全文获取类型
收费全文 | 16769篇 |
免费 | 1647篇 |
国内免费 | 352篇 |
专业分类
耳鼻咽喉 | 92篇 |
儿科学 | 290篇 |
妇产科学 | 468篇 |
基础医学 | 1092篇 |
口腔科学 | 622篇 |
临床医学 | 2325篇 |
内科学 | 2233篇 |
皮肤病学 | 352篇 |
神经病学 | 964篇 |
特种医学 | 1019篇 |
外国民族医学 | 3篇 |
外科学 | 1617篇 |
综合类 | 1607篇 |
一般理论 | 1篇 |
预防医学 | 1233篇 |
眼科学 | 148篇 |
药学 | 1948篇 |
6篇 | |
中国医学 | 2134篇 |
肿瘤学 | 614篇 |
出版年
2024年 | 49篇 |
2023年 | 456篇 |
2022年 | 566篇 |
2021年 | 905篇 |
2020年 | 796篇 |
2019年 | 865篇 |
2018年 | 809篇 |
2017年 | 762篇 |
2016年 | 630篇 |
2015年 | 667篇 |
2014年 | 1799篇 |
2013年 | 1670篇 |
2012年 | 1077篇 |
2011年 | 971篇 |
2010年 | 808篇 |
2009年 | 756篇 |
2008年 | 774篇 |
2007年 | 706篇 |
2006年 | 661篇 |
2005年 | 598篇 |
2004年 | 485篇 |
2003年 | 335篇 |
2002年 | 309篇 |
2001年 | 228篇 |
2000年 | 162篇 |
1999年 | 137篇 |
1998年 | 123篇 |
1997年 | 90篇 |
1996年 | 81篇 |
1995年 | 48篇 |
1994年 | 64篇 |
1993年 | 40篇 |
1992年 | 40篇 |
1991年 | 36篇 |
1990年 | 41篇 |
1989年 | 38篇 |
1988年 | 28篇 |
1987年 | 25篇 |
1986年 | 14篇 |
1985年 | 25篇 |
1984年 | 18篇 |
1983年 | 15篇 |
1982年 | 10篇 |
1981年 | 11篇 |
1980年 | 7篇 |
1979年 | 8篇 |
1977年 | 6篇 |
1975年 | 4篇 |
1973年 | 4篇 |
1971年 | 4篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
Sebastian Mondaca Walid K. Chatila David Bates Jaclyn F. Hechtman Andrea Cercek Neil H. Segal Zsofia K. Stadler Anna M. Varghese Ritika Kundra Marinela Capanu Jinru Shia Nikolaus Schultz Leonard Saltz Rona Yaeger 《Clinical colorectal cancer》2019,18(1):e39-e52
Background
Treatment of advanced anal squamous cell cancer (SCC) is usually with the combination of cisplatin and 5-fluorouracil, which is associated with heterogeneous responses across patients and significant toxicity. We examined the safety and efficacy of a modified schedule, FOLFCIS (leucovorin, fluorouracil, and cisplatin), and performed an integrated clinical and genomic analysis of anal SCC.Patients and Methods
We reviewed all patients with advanced anal SCC receiving first-line FOLFCIS chemotherapy – essentially a FOLFOX (leucovorin, fluorouracil, and oxaliplatin) schedule with cisplatin substituted for oxaliplatin – in our institution between 2007 and 2017, and performed deep sequencing to identify genomic markers of response and key genomic drivers.Results
Fifty-three patients with advanced anal SCC (48 metastatic; 5 unresectable, locally advanced) received first-line FOLFCIS during this period; all were platinum-naive. The response rate was 48% (95% confidence interval [CI], 32.6%-63%). With a median follow-up of 41.6 months, progression-free survival and overall survival were 7.1 months (95% CI, 4.4-8.6 months) and 22.1 months (95% CI, 16.9-28.1 months), respectively. Among all patients with advanced anal SCC that underwent sequencing during the study period, the most frequent genomic alterations consisted of chromosome 3q amplification (51%) and mutations in PIK3CA (29%) and KMT2D (22%). No genomic alteration correlated with response to platinum-containing treatment. Although there were few cases, patients with human papillomavirus-negative anal SCC did not appear to benefit from FOLFCIS, and all harbored distinct genomic profiles with TP53, TERT promoter, and CDKN2A mutations.Conclusions
FOLFCIS appears effective and safe as first-line chemotherapy in patients with advanced anal SCC and represents an alternative treatment option for these patients. 相似文献22.
Paediatric palliative care and neurodisability are two relatively new, evolving paediatric sub-specialities that have increasing relevance in the current paediatric landscape. For many people palliative care has been synonymous with end of life care, but in paediatrics it encompasses much more and is for all children with life-threatening or life-limiting conditions, from the point of diagnosis. This breadth of focus is demonstrated well through the interface between paediatric palliative care and paediatric neurodisability. In this article we explore this unique interface through the three domains of complex symptom management, advanced care planning and end of life care. We describe the practicalities involved in all three areas and highlight the importance of early referral and the process of “dual” or “parallel” planning. We cover in more depth the specific management of the symptoms: dystonia/abnormalities of muscle tone, seizures, pain, agitation, secretions, respiratory failure, and gut failure. 相似文献
23.
24.
Recognizing and managing a deteriorating patient: a randomized controlled trial investigating the effectiveness of clinical simulation in improving clinical performance in undergraduate nursing students 下载免费PDF全文
25.
26.
27.
28.
29.
30.
IntroductionDural puncture epidural (DPE) analgesia is a modification of conventional epidural analgesia that involves the intentional puncture of the dura with a spinal needle through the needle placed in the epidural space, without a medication being injected intrathecally. There have been contradictory findings regarding better analgesia and better block quality.MethodsA systematic literature search was done to identify randomized controlled trials (RCT) comparing DPE with epidural analgesia. The risk of bias was assessed with the Cochrane tool. Risk ratio and 95% confidence intervals were calculated.ResultsFive RCTs including 581 patients were identified. One RCT on caesarean section was excluded. Single studies suggested slightly better analgesia by finding a median time to achieve sufficient analgesia of two minutes less in the DPE group, a higher number of women having a pain score <10/100 at 20 min, a reduction in the number of epidural top-ups and better sacral spread. The studies did not show a difference between DPE and epidural analgesia for catheter replacement or manipulation rates, the incidence of intravascular placement or unilateral block.ConclusionThere is a lack of clear evidence on either the benefits or the risks of the DPE technique, such that a recommendation for or against its routine use is premature. Two of the three studies showing a beneficial effect of DPE came from the same institution and replication of the findings by other groups is warranted. 相似文献